Target	Discovery	Preclinical PoC	Humanized mAbs	Clinical Development
PTT256	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
PTT372	>>>>>>>>>>>>>
PTT163	>>>>>>>>>>>>>
PTT376	>>>>>>>>>>>>>
PTT375	>>>>>>>>>>>>>
PTT072	>>>>>>>>>>>>>
PTT263	>>>>>>>>>>>>>
PTT085	>>>>>>>>>>>>>

 

 

 

  

PTT256 mAb

We are developing a humanized monoclonal antibody (mAb) therapeutic that targets PTT256, one of our proprietary targets. PTT256 is a cell surface single pass transmembrane protein up-regulated in prostate cancer stem cells. This is a novel and attractive therapeutic target for prostate cancer as: 

• It is up-regulated in cancer stem cells relative to benign cells and expressed in transit  amplifying cells
• It is not significantly expressed in other tissues
• We have shown that inhibition of this target prevents tumour initiation in vivo
• PTT256 is localised on the cell surface in primary human prostate cancer cells: cancer stem cells (CSCs) and transit-amplifying cells (TA)